EMEA-002969-PIP01-21
Key facts
Active substance |
|
Therapeutic area |
Other
|
Decision number |
P/0249/2021
|
PIP number |
EMEA-002969-PIP01-21
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of chronic kidney disease
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
AstraZeneca AB
Tel. +46 8 553 24400 |
Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|